A study about safety, effectiveness and improvement in quality of life achieved by duloxetine and desvenlafaxine in adult patients of diabetic peripheral neuropathy

A comparative study of safety, efficacy and quality of life outcomes of duloxetine with desvenlafaxine in adult patients of diabetic peripheral neuropathy : A Randomized Controlled Academic Trial. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096585

Enrollment

100

Registered

2025-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Duloxetine: Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). In diabetic peripheral neuropathy, duloxetine demonstrates efficacy in reducing neuropathic pain, improvi

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients willing to give written informed consent and are diagnosed with diabetic peripheral neuropathy will be included.

Exclusion criteria

Exclusion criteria: 1. Less than 18 years of age 2. Pregnant and lactating women 3. Patients diagnosed with epilepsy 4. Chronic alcohol consumers 5. Participants with neuropathy due to other causes like vitamin B12 deficiency, thyroid dysfunction, occupational exposure to heavy metals like arsenic, lead, etc. 6. Patients allergic or with known contraindications to either duloxetine or desvenlafaxine

Design outcomes

Primary

Measure	Time frame
A comparative study of safety, efficacy, quality of life outcomes of duloxetine with desvenlafaxine in adult patients of diabetic peripheral neuropathy.Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactPrarthana Deori

Dr. Rajendra Prasad Govt. Medical College, Kangra at Tanda

atalsood7@gmail.com9418063191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026